These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20685298)

  • 1. Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate postresistance therapy.
    Bertolini F; Marighetti P; Shaked Y
    Biochim Biophys Acta; 2010 Dec; 1806(2):131-7. PubMed ID: 20685298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
    Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
    Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis: a target for cancer therapy.
    Tortora G; Melisi D; Ciardiello F
    Curr Pharm Des; 2004; 10(1):11-26. PubMed ID: 14754402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
    Cao Y
    Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic therapy: Markers of response, "normalization" and resistance.
    El Alaoui-Lasmaili K; Faivre B
    Crit Rev Oncol Hematol; 2018 Aug; 128():118-129. PubMed ID: 29958627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance associated with antiangiogenesis therapy.
    Eikesdal HP; Kalluri R
    Semin Cancer Biol; 2009 Oct; 19(5):310-7. PubMed ID: 19524042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic strategies and agents in clinical trials.
    Rosen L
    Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic therapies: going beyond their limits.
    Moserle L; Jiménez-Valerio G; Casanovas O
    Cancer Discov; 2014 Jan; 4(1):31-41. PubMed ID: 24356098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignancies.
    Zhao C; Zeng Y; Kang N; Liu Y
    Drug Dev Res; 2024 Sep; 85(6):e22257. PubMed ID: 39245913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
    Sessa C; Guibal A; Del Conte G; Rüegg C
    Nat Clin Pract Oncol; 2008 Jul; 5(7):378-91. PubMed ID: 18560389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.
    Gagne P; Akalu A; Brooks PC
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical biomarkers of angiogenesis inhibition.
    Brown AP; Citrin DE; Camphausen KA
    Cancer Metastasis Rev; 2008 Sep; 27(3):415-34. PubMed ID: 18414993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to antiangiogenic therapies.
    Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA
    Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic drugs and tyrosine kinases.
    Tímár J; Döme B
    Anticancer Agents Med Chem; 2008 Jun; 8(5):462-9. PubMed ID: 18537529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.
    Jain RK
    Cancer Cell; 2014 Nov; 26(5):605-22. PubMed ID: 25517747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Following up tumour angiogenesis: from the basic laboratory to the clinic.
    Orgaz JL; Martínez-Poveda B; Fernández-García NI; Jiménez B
    Clin Transl Oncol; 2008 Aug; 10(8):468-77. PubMed ID: 18667377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of response and resistance to antiangiogenic therapy.
    Jain RK; Duda DG; Willett CG; Sahani DV; Zhu AX; Loeffler JS; Batchelor TT; Sorensen AG
    Nat Rev Clin Oncol; 2009 Jun; 6(6):327-38. PubMed ID: 19483739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.
    Ebos JM; Kerbel RS
    Nat Rev Clin Oncol; 2011 Mar; 8(4):210-21. PubMed ID: 21364524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Contribution of Angiogenesis to the Process of Metastasis.
    Bielenberg DR; Zetter BR
    Cancer J; 2015; 21(4):267-73. PubMed ID: 26222078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.